Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers

NCT02657876 is registered in ClinicalTrials.gov with Stratatech, a Mallinckrodt Company as lead sponsor.

NCT NCT02657876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02657876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Lead sponsor
Stratatech, a Mallinckrodt Company
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2018
Completion date
May 28, 2019
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetic foot ulcer, non-healing wound